Merck KGaA

News

Merck taps Caris’ AI expertise in ADC-focused alliance

Germany’s Merck KGaA has partnered with techbio company Caris Discovery in a $1.4 billion alliance that will apply artificial intelligence to the design of antibody-drug c

News

Merck bets on Inspirna’s colorectal cancer drug ompenaclid

Germany’s Merck KGaA is paying $45 million upfront for rights to a potentially first-in-class drug for colorectal cancer (CRC) being developed by New York biotech Inspirna

News

Merck pummelled as MS hope evobrutinib dies in phase 3

Germany’s Merck KGaA is facing a big hole in its late-stage pipeline after multiple sclerosis (MS) candidate evobrutinib missed the mark in two phase 3 trials, spelling th

News

Merck grabs late-stage oncology drug from China’s Abbisko

Germany’s Merck KGaA is paying Chinese biotech Abbisko Therapeutics $70 million upfront for rights to a drug in phase 3 testing for tenosynovial giant cell tumour (TGCT), a rare disea

News

Merck signs €1.4bn cancer alliance with China’s Hengrui

Germany’s Merck KGaA has reached a deal with Chinese pharma company Jiangsu Hengrui that covers a pair of cancer drugs, including a ‘next-generation’ PARP inhibitor and an

News

Merck puts $1.3bn into AI via Exscientia, BenevolentAI deals

German group Merck has revved up its artificial intelligence-powered drug discovery with partnerships with two UK companies – Exscientia and BenevolentAI – that will focus

Merck taps Caris’ AI expertise in ADC-focused alliance

Merck bets on Inspirna’s colorectal cancer drug ompenaclid

Merck pummelled as MS hope evobrutinib dies in phase 3

Merck grabs late-stage oncology drug from China’s Abbisko

Merck signs €1.4bn cancer alliance with China’s Hengrui

Merck puts $1.3bn into AI via Exscientia, BenevolentAI deals

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Merck KGaA

Editor's Picks